Company Management

Dr. Jiang has served as President and/or Chairman for multiple biotech companies in Taiwan, including PhytoHealth Corporation from 1998 to 2009 and AmCad BioMed Corporation from 2008 to 2009. At Phyto Health, the PG2 Lyo Injectable product was developed for cancer patients experiencing difficulty recovering from severe fatigue. In 2010, PG2 Lyo Injection became one of the first drugs developed in Taiwan to receive NDA approval from the Taiwan Food and Drug Administration. It began sales in Taiwan in 2012.

In addition, Dr. Jiang is a director of various biotech associations, such as the Taiwan Bio Industry Organization (Taiwan) from 2006 to 2008 and the Chinese Herbs and Biotech Development Association in Taiwan from 2003 to 2006. He was an assistant professor at the University of Illinois from 1981 to 1987 and an associate professor at Rutgers from 1987 to 1990.

Uttam Patil comes from research background and has worked on several multidisciplinary projects during his time in academics. Prior to joining ABVC, He served as a post-doctoral fellow at National Taiwan Normal after receiving his Ph.D. from the National Tsing Hua University, Department of Chemistry.

Uttam Patil serves as the R&D Manager of Rgene Corporation, a Taiwanese company committed to developing new plant-based drugs and combination cancer therapies to provide better medical assistance for improving the patient’s quality of life. He also serves as Chief Operating & Scientific Officer BioKey, Inc., a GMP-certified facility that provides its clients with integrated pharmaceutical services, including early-phase product development, formulation development, analytical development & drug product manufacturing.

Leeds Chow, was appointed as the Company’s Chief Financial Officer and Principal Accounting Officer on September 4, 2022. He has served as a Financial Controller of the Company from March 2021 to August 2022. Mr. Chow has over 12 years of experience in Audit and Financing Industry. He has served as the finance manager in a family office, in charge of managing investment portfolios, handling financial and operating aspects.

He has also worked in a local investment company in Hong Kong, serving as a financial advisor during the Hong Kong Initial Public Offering process, as well as preparing opinion letters as an independent financial advisor for transactions for Hong Kong listed companies. Mr. Chow graduated in University of California, Santa Barbara, with a Bachelor of Arts degree, majoring in Business Economics with Accounting Emphasis.